vanderbilt, one of the hotteste universities in the country, to associate deans at the peabody schools. ffice ofoffice of equity, diveru and inclusion were caught doing somethinght thatg that would get students tossed out after univet the tragic killings. michigan state universityh an nikole joseph and haseena hootin felt the need to send out a campus wide email nee to reflect on the shooting. one problem they use t the artificial intelligence app thechat to write it for them. c well, no big surprise that the bot use the typical liberal dii blather and redundant expressions. this was part of it.e reshootins the recent michigan shootings eacha tragic reminder of the importance of taking care of each other, particularly ine the context of creating inclusive environments. now thes now, thesee women were so sloppe and so lazy that they didn t notice the small print ate the end of the actual letter, which read paraphrased fromsed r open eyeom opes, a language modi personal communi
Mirna Chehade, MD, MPH, discusses ongoing trials for emerging therapies in eosinophilic esophagitis (EoE), her views on the use of combination therapies, and the importance of shared decision-making for the chronic management of EoE throughout the different phases of a patient’s life.
Mirna Chehade, MD, MPH, discusses the challenges faced by patients with eosinophilic esophagitis (EoE), including the absence of predictive factors for personalized treatment, the social implications of dietary restrictions, and the need for invasive procedures, while emphasizing the importance of regularly scheduled follow-up visits to address medical, nutritional, and psychosocial factors for better outcomes.
Mirna Chehade, MD, MPH, discusses the impact of adverse events on influencing treatment decisions for eosinophilic esophagitis (EoE) in pediatric patients, and considerations for the use of biologics.
We sat down with Evan Dellon, MD, MPH, to discuss the use of dupilumab in pediatric EoE patients, with the agent gaining FDA approval as the first and only indication for this patient population on January 25, 2024.